论文部分内容阅读
目的探讨奥美拉唑联合莫沙必利治疗哮喘合并胃食管反流病的疗效。方法选取哮喘合并胃食管反流患者58例,随机分为观察组(联合用药组)与对照组(单一用药组)。观察组采用吸入布地奈德/福莫特罗联合抗反流方案即奥美拉唑联合莫沙必利,对照组单独吸入布地奈德/福莫特罗粉剂,比较治疗前后两组患者哮喘症状评分、胃食管反流症状评分及两组患者的临床疗效。结果两组患者治疗前哮喘症状评分、胃食管反流症状评分比较差异未见统计学意义(P>0.05),治疗后观察组胃食管反流病史(GERD)症状评分下降,差异有统计学意义(P<0.01),对照组GERD症状评分未见明显变化(P>0.05);两组哮喘症状评分较治疗前均显著下降(P<0.01),治疗后观察组较对照组症状评分差异有统计学意义(P<0.01),两组患者总有效率比较差异有统计学意义(P<0.05)。结论在治疗哮喘合并胃食管反流病患者时,在控制哮喘的同时给予抗反流治疗,临床疗效显著,值得临床推广应用。
Objective To investigate the efficacy of omeprazole combined with mosapride in the treatment of asthma with gastroesophageal reflux disease. Methods Fifty-eight asthma patients with gastroesophageal reflux disease were randomly divided into observation group (combination group) and control group (single group). In the observation group, inhalation of budesonide / formoterol combined with anti-reflux regimen omeprazole combined with mosapride, the control group inhaled budesonide / formoterol powder alone, comparing the two groups of patients before and after treatment of asthma symptoms Score, gastroesophageal reflux symptom score and the clinical efficacy of two groups of patients. Results The scores of asthma symptom scores and gastroesophageal reflux symptom scores before treatment were not significantly different between the two groups (P> 0.05), and the scores of GERD symptom scores decreased in the observation group after the treatment, with significant difference (P <0.01). There was no significant change in GERD symptom scores in the control group (P> 0.05). The scores of asthma symptoms in both groups were significantly decreased compared with those before treatment (P <0.01). There was statistical difference between the observation group and the control group (P <0.01). There was significant difference between the two groups in the total effective rate (P <0.05). Conclusion In the treatment of asthma with gastroesophageal reflux disease in patients with asthma control at the same time given anti-reflux therapy, clinical efficacy is significant, worthy of clinical application.